Authors Reply on Proton vs Photon Therapy for Oropharyngeal Cancer

This correspondence features the authors' reply to comments by David J Sher regarding a phase 3 clinical trial comparing intensity-modulated photon radiation therapy (IMRT) and intensity-modulated proton therapy (IMPT) for treating oropharyngeal cancer. The authors highlight a key finding that proton therapy allows for de-intensified chemoradiation, significantly reducing high-grade toxicities and gastrostomy tube dependency. Specifically, the rate of gastrostomy tube dependency was 40.2% in the IMRT group compared to 26.8% in the IMPT group. Sher had expressed concern that the reported rates of severe xerostomia were higher in this trial than in the previous RTOG 1016 study, noting that 45% of IMPT patients and 33% of IMRT patients experienced severe dry mouth. The authors address these concerns by contextualizing their findings against the RTOG 1016 data, where 61.5% of patients required gastrostomy tubes. This exchange underscores the ongoing evaluation of toxicity profiles and quality-of-life outcomes in advanced radiation therapies for head and neck cancers, emphasizing the potential benefits of proton therapy in reducing treatment-related burdens.